CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-12 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −15,396 | $357.63 | $5.5M | 35,001 |
| 2026-08-12 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −20,899 | $358.41 | $7.5M | 14,102 |
| 2026-08-12 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −14,102 | $359.12 | $5.1M | 0 |
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +812 | $194.47 | $158K | 812 |
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +1,058 | $213.32 | $226K | 1,870 |
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +796 | $159.03 | $127K | 2,666 |
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −2,666 | $360.00 | $960K | 0 |
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −10,556 | 0 | ||
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −13,754 | 57,369 | ||
| 2026-08-11 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −10,348 | 88,582 | ||
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −13,695 | $359.32 | $4.9M | 112,104 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −8,081 | $360.33 | $2.9M | 104,023 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −14,569 | $361.47 | $5.3M | 89,454 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −11,568 | $362.34 | $4.2M | 77,886 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −13,403 | $363.45 | $4.9M | 64,483 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −5,211 | $364.31 | $1.9M | 59,272 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −3,176 | $365.26 | $1.2M | 56,096 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,200 | $366.31 | $440K | 54,896 |
| 2026-08-11 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −4 | $367.00 | $1K | 54,892 |
| 2026-08-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −67 | $350.00 | $23K | 240,743 |
Page 4 of 71 · 1,406 trades